Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges
Essential thrombocythemia (ET) occurring with breast cancer is uncommon; the therapeutic approach varies and poses a challenge. A 65-year-old female presented to us after being diagnosed with hormone positive, HER2-negative infiltrating ductal carcinoma. She had a platelet count of 600 thou/cu mm. H...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2018/2080185 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850226522624884736 |
|---|---|
| author | Karan Seegobin Bharatsinh Gharia Satish Maharaj Lara Zuberi |
| author_facet | Karan Seegobin Bharatsinh Gharia Satish Maharaj Lara Zuberi |
| author_sort | Karan Seegobin |
| collection | DOAJ |
| description | Essential thrombocythemia (ET) occurring with breast cancer is uncommon; the therapeutic approach varies and poses a challenge. A 65-year-old female presented to us after being diagnosed with hormone positive, HER2-negative infiltrating ductal carcinoma. She had a platelet count of 600 thou/cu mm. Her JAK2 mutation was positive. Bone marrow biopsy showed increased megakaryocytes. She was diagnosed with ET in the setting of breast cancer. She underwent breast conservation surgery after which aspirin was resumed. Anticipating thrombocytopenia during chemotherapy and given the absence of data combining hydroxyurea with standard chemotherapy used for breast cancer, we felt it prudent to delay cytoreductive therapy for her ET until after completion of breast cancer treatment. Her average platelet count during chemotherapy was 480 thou/cu mm with the lowest being 377 thou/cu mm. Her platelet count remained at goal between 300 and 350 thou/cu mm after four months of hydroxyurea. |
| format | Article |
| id | doaj-art-54ee742cbcfd4671bb12f0dab161b557 |
| institution | OA Journals |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-54ee742cbcfd4671bb12f0dab161b5572025-08-20T02:05:03ZengWileyCase Reports in Hematology2090-65602090-65792018-01-01201810.1155/2018/20801852080185Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic ChallengesKaran Seegobin0Bharatsinh Gharia1Satish Maharaj2Lara Zuberi3Department of Internal Medicine, University of Florida College of Medicine, Jacksonville, FL 32209, USADepartment of Hematology and Oncology, University of Florida College of Medicine, Jacksonville, FL 32209, USADepartment of Internal Medicine, University of Florida College of Medicine, Jacksonville, FL 32209, USADepartment of Hematology and Oncology, University of Florida College of Medicine, Jacksonville, FL 32209, USAEssential thrombocythemia (ET) occurring with breast cancer is uncommon; the therapeutic approach varies and poses a challenge. A 65-year-old female presented to us after being diagnosed with hormone positive, HER2-negative infiltrating ductal carcinoma. She had a platelet count of 600 thou/cu mm. Her JAK2 mutation was positive. Bone marrow biopsy showed increased megakaryocytes. She was diagnosed with ET in the setting of breast cancer. She underwent breast conservation surgery after which aspirin was resumed. Anticipating thrombocytopenia during chemotherapy and given the absence of data combining hydroxyurea with standard chemotherapy used for breast cancer, we felt it prudent to delay cytoreductive therapy for her ET until after completion of breast cancer treatment. Her average platelet count during chemotherapy was 480 thou/cu mm with the lowest being 377 thou/cu mm. Her platelet count remained at goal between 300 and 350 thou/cu mm after four months of hydroxyurea.http://dx.doi.org/10.1155/2018/2080185 |
| spellingShingle | Karan Seegobin Bharatsinh Gharia Satish Maharaj Lara Zuberi Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges Case Reports in Hematology |
| title | Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
| title_full | Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
| title_fullStr | Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
| title_full_unstemmed | Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
| title_short | Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
| title_sort | coexistent breast cancer and essential thrombocythemia how we addressed the therapeutic challenges |
| url | http://dx.doi.org/10.1155/2018/2080185 |
| work_keys_str_mv | AT karanseegobin coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges AT bharatsinhgharia coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges AT satishmaharaj coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges AT larazuberi coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges |